The U.S. Food and Drug Administration (FDA) will hold a public advisory committee meeting of the National Mammography Quality Assurance Advisory Committee on September 15 in Gaithersburg, MD.
The agenda will include the following:
- Current compliance trends with the Mammography Quality Standards Act (MQSA)
- A proposal to use the agency's inspection program to enhance image quality
- A discussion of the quality control manual for full-field digital mammography from the American College of Radiology (ACR)
- A presentation of current issues related to breast density and cancer screening, including how these might affect a possible MQSA requirement for reporting breast density
- Future challenges for MQSA, such as the role of synthesized 2D images
Meeting attendees may present data, information, or perspectives on these agenda items either orally or in writing. Written responses must be submitted before September 7.












![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)





